Tag Archives: White House

Obama Budget Takes Slap at Pharma

Despite a slight boost in funding for the Food and Drug Administration and stronger tax incentives for investment in R&D, significant changes in Medicare drug reimbursement and coverage policies have biopharmaceutical companies up in arms.
Posted in Biotech, IP, Legal, R&D, Regulatory | Also tagged , , | Leave a comment

Sequestration: How Big a Hit for FDA, Research and Pharma?

The greatly feared federal budget sequestration mandate went into effect March 1, and, initially, the impact was fairly muted. The stock market soared, employment rose and government workers continued on their jobs. Federal agencies, including the Food and Drug Administration (FDA), launched initiatives to comply with the mandated 5% across-the-board cut in spending (in reality […]
Posted in FDA, healthcare, leadership, Legal, R&D | Also tagged , , , , , , | Leave a comment

Will Healthcare Reform Pay Off?

Written by Jordan Melnick Members of Congress are in for a hard landing when they get back from recess in early September. After four weeks at home in their districts, the debate will heat up again as they resume the arduous process of crafting the biggest piece of President Obama’s domestic agenda. With the president […]
Posted in Regulatory | Also tagged , , , , , , | Leave a comment

Tauzin to Boehner: Don’t “Bully” Me

Image via Wikipedia PhRMA chief Billy Tauzin so far shows no sign of waving the white flag in response to an accusatory missive from House Minority Leader Rep. John Boehner bludgeoning his former Republican colleague for leading the drug industry’s support of President Obama’s healthcare reform effort. Pointedly CC’d to pharma CEOs – Tauzin’s employers—and […]
Posted in Regulatory | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta